<u>Original research article</u> Inhibition of α-amylase and α-glucosidase by *Acanthus montanus* leaf extracts

4 5

1

2

3

ABSTRACT

6 7

Aim: The aim of this study was to determine the *in-vitro* anti-diabetic potentials of *Acanthus montanus*. This was done by assessing the inhibitory effect of both methanol and ethylacetate extracts of the plant on the activities of α -amylase and α -glucosidase.

Study design: The design included extraction of *A. montanus* leaves with methanol and ethanol and subsequent evaluation of the extracts for possible hypoglycemic effect.

Place and Duration of Study: The leaves of *A. montanus* were obtained from Badagry Area of Lagos, Nigeria in December 2012. The plant was identified and authenticated by Dr. S. O. Shosanya of the Forestry Research Institute of Nigeria (FRIN), Ibadan, Nigeria.

Methodology: The powdered leaves were extracted with ethylacetate and methanol separately for 24 h. The resulting infusions were decanted, filtered and evaporated in a rotary evaporator. Dried extracts were weighed and dissolved in dimethylsulphoxide (DMSO) to yield a stock solution from which lower concentrations were prepared. The inhibitory actions of both extracts against α -amylase and α -glucosidase were determined established procedures.

Results: The results showed that of the two extracts, methanol showed more inhibitory action than ethanol against both α -amylase and α -glucosidase. Lineweaver-Burk plot also depicted that the methanol extract inhibited both α -amylase and α -glucosidase in a non-competitive and competitive manner respectively.

Conclusion: It can be concluded that the hypoglycemic effect of extracts of *A. montanus* may be as a result of the inhibition of these enzymes (α -amylase and α -glucosidase). This observation may be elicited by the presence of some phytochemicals present in the extracts.

Keywords: Acanthus montanus, α -amylase, α -glucosidase, antidiabetic

8 9

10 **1. INTRODUCTION**

11

12 Diabetes is a metabolic disease which is as old as mankind and its incidence is considered to be high (4-5%) all over the world [1]. It is also a major cause of disability and 13 hospitalization and results in significant financial burden [2]. It is considered a "modern day 14 15 epidemic" and is rightly recognized as a global public health issue. The number of people suffering from the disease worldwide is increasing at an alarming rate with a projected 552 16 17 million people likely to be diabetic by the year 2035 as against 382 million estimated in 2014 [3]. There is need for the discovery of anti-diabetic agents from natural sources due to 18 19 limited efficacy and serious side effects associated with synthetic drugs which include 20 hypoglycaemia, chronic tissue damage and death [4].

21 Acanthus montanus (Nees) T. Anderson (Acanthaceae) is a small shrub with sparse 22 branches and soft stems. It is commonly known as Mountain Thistle or Bears Breech and is 23 believed to have originated from West Africa [5]. It is used in traditional medicine in the 24 Southern part of Nigeria under the names; 'Mafowokan omomi', 'Agamsoso' and 'Agameru'. 25 It is also used in different parts of Africa in the treatment of various illnesses such as cough, 26 epilepsy, pain, dysmenorrhoea, hypertension, false labour, syphilis, skin infections and 27 diabetes mellitus [6, 7]. The pharmacological properties of this plant which include hepatoprotective [8], tocolytic [9], anti-inflammatory, antimicrobial and immunological 28 properties [5] have been reported by several authors. Nana et al. [10] reported the safety of 29

30 this plant in pregnant rats as well as their offspring while Djami et al. [11] also stated its 31 tolerance in female rats at concentration greater than 1000 mg/kg body weight. Although, 32 there is a study on the hypoglycemic potential of the methanolic extract of this plant [7], there 33 is dirt of information on the possible mechanism by which it elicits its hypoglycemic action.

34 It is well known that any anti-diabetic agent can act by one or more of the following 35 mechanisms; pancreatic β -cells regeneration, insulin secretion, mimicking the action of 36 insulin, inhibition of carbohydrate metabolizing enzymes as well as slowing down the 37 absorption of sugars from the gut [12]. The aim of this study was to assess the effect of leaf extracts of Nigerian grown A. montanus on diabetes-related enzymes (a-amylase and a-38 39 glucosidase) as well as its mode of inhibition of these enzymes. In our previously study, the 40 anti-diabetic potentials of some other medicinal plants grown in Nigeria have been reported 41 [13].

42 43

2. MATERIAL AND METHODS

44 45

2.1 Chemicals and reagents 46 47

48 Porcine pancreatic α -amylase, rat intestinal α -glucosidase and paranitrophenylglucopyranoside were products of Sigma-Adrich Co., St Louis, USA while starch soluble 49 50 (extra pure) was obtained from J. T. Baker Inc., Phillipsburg, USA. Other chemicals and 51 reagents were of analytical grade and the water used was glass-distilled.

52 53

2.2 Plant sample

54 55

56 The leaves of Acanthus montanus were obtained from Badagry Area of Lagos, Nigeria, in December 2012. The plant sample was identified and authenticated by the taxonomist; Dr. 57 S. O. Shosanya of the Forestry Research Institute of Nigeria (FRIN), Ibadan, Nigeria and 58 voucher specimen (FHI 109720) was deposited in the Institute's herbarium. The leaves were 59 air-dried, pulverized and kept in airtight plastic bags. 60

61

62 2.2.1 Preparation of extracts

63

64 The powdered leaves were divided into two portions of 10 g each and these were extracted 65 with ethylacetate and methanol respectively. The mixtures were left to steep in covered 66 conical flasks for 24 h, the flasks were shaken at interval and kept still to allow the plant 67 material to settled at the bottom of the flask. The resulting infusions were decanted, filtered and evaporated in a rotary evaporator (Cole Parmer SB 1100, Shangai, China). Dried 68 69 extracts were weighed and dissolved in dimethylsulphoxide (DMSO) to yield a stock solution 70 from which lower concentrations were prepared. All extracts were stored at 4°C prior to 71 analysis.

72

73 2.3 α-Amylase inhibitory assay

74 This assay was carried out using a modified procedure of McCue and Shetty [14]. A total of 75 250 µL of extract was placed in a test tube and 250 µL of 0.02 M sodium phosphate buffer (pH 6.9) containing α -amylase solution was added. This solution was pre-incubated at 25°C 76 77 for 10 min, after which 250 µL of 1% starch solution in 0.02 M sodium phosphate buffer (pH 78 6.9) was added at timed intervals and then incubated at 25℃ for 10 min. The reaction was 79 terminated by adding 500 µL of dinitrosalicylic acid (DNS) reagent. The tubes were then 80 incubated in boiling water for 5 min and cooled to room temperature. The reaction mixture 81 was diluted with 5 mL of distilled water and the absorbance was measured at 540 nm using
82 a spectrophotometer (Spectrumlab S23A, Globe Medical England). The control and blank
83 solutions were prepared using the same procedure by replacing the extract with DMSO and
84 distilled water respectively. The α-amylase inhibitory activity was calculated as percentage
85 inhibition as follows;

86 87

89

where $\Delta A_{control} = A_{control} - A_{blank}$ and $\Delta A_{extract} = A_{extract} - A_{blank}$

% Inhibition = $[(\Delta A_{control} - \Delta A_{extract})/A\Delta_{control}] \times 100$

90 Concentrations of extracts resulting in 50% inhibition of enzyme activity (IC_{50}) were 91 determined graphically.

92 93

94 **2.3.1 Mode of α-amylase inhibition**

95 The mode of inhibition of α -amylase by the extract was conducted using the most potent 96 extract according to the modified method described by Ali et al. [15]. Briefly, 250 µL of the (5 97 mg/mL) extract was pre-incubated with 250 μL of α-amylase solution for 10 min at 25°C in 98 one set of tubes. In another set of tubes α -amylase was pre-incubated with 250 µL of phosphate buffer (pH 6.9). Then, 250 µL of starch solution at increasing concentrations (0.3– 99 100 5.0 mg/mL) was added to both sets of reaction mixtures to enable the reaction to commenced. The mixture was then incubated for 10 min at 25°C, and then boiled for 5 min 101 102 after addition of 500 µL of DNS to stop the reaction. The amount of reducing sugars 103 released was determined spectrophotometrically using a maltose standard curve and converted to reaction velocities. A double reciprocal (Lineweaver-Burk) plot (1/v versus 1/[S]) 104 105 where v is reaction velocity and [S] is substrate concentration was plotted to determine the 106 mode of inhibition.

107

108 **2.4 α-Glucosidase inhibitory assay**

109 The effect of the plant extracts on the activity of α -glucosidase was determined according to 110 the method described previously by Kim et al. [16]. The substrate solution, p-nitropheynyl glucopyranoside (pNPG) was prepared in 20 mM phosphate buffer (pH 6.9). Also, 100 µL of 111 112 α-glucosidase (E.C. 3.2.1.20) was pre-incubated with 50 μL of the different concentrations of the extracts for 10 min. Then, 50 µL of 3.0 mM pNPG dissolved in 20 mM phosphate buffer 113 (pH 6.9) was added to start the reaction. The reaction mixture was incubated at 37°C for 20 114 115 min and stopped by adding 2 mL of 0.1 M Na₂CO₃. The α -glucosidase activity was 116 determined by measuring the yellow coloured para-nitrophenol released from pNPG at 405 117 nm. The control and blank were prepared using the same procedure by replacing the extract 118 with DMSO and distilled water respectively. Percentage inhibition was calculated thus;

119 120

% Inhibition =
$$[(\Delta A_{control} - \Delta A_{extract})/A\Delta_{control}] \times 100$$

121 where
$$\Delta A_{control} = A_{control} - A_{blank}$$
 and $\Delta A_{extract} = A_{extract} - A_{blank}$

122

123 Concentrations of extracts resulting in 50% inhibition of enzyme activity (IC_{50}) were 124 determined graphically

125

126 **<u>2.4.1 Mode of α-glucosidase inhibition</u>**

127

128 The mode of inhibition of α -glucosidase by the extracts was determined using the extract 129 with the lowest IC₅₀ according to the modified method described by Ali et al. [15]. Briefly, 50 130 µL of the (5 mg/mL) extract was pre-incubated with 100 µL of α -glucosidase solution for 10 131 min at 25 \mathcal{C} in one set of tubes. In another set of tubes, α -glucosidase was pre-incubated with 50 µL of phosphate buffer (pH 6.9). Thereafter 50 µL of pNPG at increasing 132 133 concentrations (0.63 - 2.0 mg/mL) was added to both sets of reaction mixtures to start the 134 reaction. The mixture was then incubated for 10 min at 25°C after which 500 µL of Na₂CO₃ 135 was added to stop the reaction. The amount of reducing sugars released was determined 136 spectrophotometrically using a para-nitrophenol standard curve and converted to reaction 137 velocities. A double reciprocal (Lineweaver-Burk) plot (1/v versus 1/[S]) where v is reaction 138 velocity and [S] is substrate concentration was plotted to determine the mode of inhibition of 139 the enzyme.

140

141 **2.5 Statistical analysis**

142 143 Statistical analysis was performed using GraphPad Prism 5 statistical package (GraphPad 144 Software, USA). The data were analysed by one way analysis of variance (ANOVA) followed 145 by Bonferroni test. All the results were expressed as mean ± SEM for triplicate 146 determinations.

147

148 3. RESULTS AND DISCUSSION

149

Figure 1 showed the percentage inhibition of α -amylase by methanol and ethylacetate extracts of *A. montanus*. There were no significant differences between the extracts at low concentrations (0.32 - 0.63 mg/mL). However at higher concentrations, the ethylacetate extract exhibited significantly higher percentage inhibition of the enzyme. The higher percentage inhibition of the enzyme displayed by the ethylacetate extract was corroborated by its lower IC₅₀ value compared to that of methanol extract (Table 1).


156

157

158 Table 1: IC_{50} values for α -amylase and α -glucosidase inhibitory potential of *A. montanus* leaf 159 extracts

| Extracts | IC₅₀ (mg/mL) | |
|--------------|---------------------|--------------------------|
| | α-Amylase | α-Glucosidase |
| Methanol | 2.87 ± 0.02^{a} | 1.65 ± 0.02^{a} |
| Ethylacetate | 2.39 ± 0.04^{b} | 7.10 ± 0.15 ^⁵ |
| Acarbose | 2.60 ± 0.01^{a} | $0.63 \pm 0.00^{\circ}$ |

160



161 162

Fig 1: Inhibitory potency of A. montanus leaf extracts against α-amylase activity. The values are 163 expressed as means ± SEM of triplicate determinations. Means not sharing a common letter at the same concentration are significantly different (P = .05) 164

165

166 However, the Lineweaver-Burk plot of the mode of inhibition of α -amylase by the methanol 167 extract of this plant showed that it is a non-competitive inhibitor of the enzyme (Figure 2).







Fig 2: Mode of inhibition of α-amylase by methanol extract of A. montanus

170 171 The percentage of inhibition of α -glucosidase by the extracts of A. montanus is shown in Fig. 172 3. At all concentrations tested, methanol extract exhibited significantly higher (P=.05) 173 percentage inhibition of this enzyme compared to ethylacetate extract. However, the 174 inhibition of the enzyme by both extract was dose-dependent. This is supported by the lower 175 IC₅₀ value for ethanol extract compared to methanol extract. Kinetic analysis of the mode of 176 inhibition of the enzyme with the aid of Lineweaver-Burk plot showed that the ethanol extract inhibited the enzyme in a competitive manner (Figure 4). 177




178 179

Fig 3: Inhibitory potency of A. montanus leaf extracts against α-glucosidase activity. The values are 180 expressed as means ± SEM of triplicate determinations. Means not sharing a common letter at the same concentrations are significantly different (P = .05)

181

182



183

184 Fig 4: Mode of inhibition of α-glucosidase by ethylacetate extract of *A. montanus*

185

186 The management of hyperglycemia is the hallmark of treatment in diabetes. A convenient therapeutic approach for decreasing postprandial hyperglycemia is to retard the digestion 187 and absorption of carbohydrates. This is done through the inhibition of carbohydrate 188 hydrolyzing enzymes, α -amylase and α -glucosidase, in the digestive tract [17]. Though, 189 synthetic α -glucosidase inhibitors such as acarbose and voglibose are presently in use but 190 191 are bedeviled by undesirable side effects such as nausea, hypoglycaemia, diarrhoea and 192 liver failure [14], which necessitated this study.

193

194 The present study showed that the ethylacetate extract of A. montanus produced stronger 195 inhibition of a-amylase than methanol extract. However, methanol extract will be more

suitable to be used as anti-diabetic agent because of its mild inhibition of the enzymes, 196 197 possessing higher IC₅₀ than ethylacetate extract and acarbose. Previous studies have 198 shown that any prospective anti-diabetic agent should be a mild inhibitor of α -amylase so as 199 to prevent the drawback of synthetic drugs (like acarbose), which occur due to the excessive 200 inhibition of the enzyme resulting in the abnormal bacterial fermentation of undigested 201 carbohydrates in the colon [18, 19]. Therefore, the Lineweaver-Burk plot of the inhibition 202 depicted that methanol extract of A. motanus inhibited the enzyme in a non-competitive 203 manner. This implies that the active components in the extract binds to a site other than the 204 active site of the enzyme and combines with either free enzyme or the enzyme-substrate 205 complex, possibly interfering with the action of both [20].

206

207 The stronger inhibition of α -glucosidase by the methanol extract of A. montanus at all 208 concentrations tested compared to ethylacetate extract, culminated into having low IC_{50} 209 which is also desirable of a good antidiabetic drug. The competitive inhibition of the enzyme 210 by methanol extract of A. montanus suggest that the inhibitory component(s) in the plant 211 binds reversibly to the active site of the enzyme and occupies it in a mutually exclusive 212 manner with the substrate [21, 22]. This may due to structural similarity between the inhibitor 213 and the normal substrate (disaccharides), thereby slowing down the production of glucose 214 and reducing hyperglycemia.

215

Tannins are phenolic compounds which have been found to induce phosphorylation of insulin receptors and translocation of glucose transporter, thereby helping in the reduction of blood glucose level [23]. Studies have also shown the antioxidant and antidiabetic properties of saponins from different medicinal plants [24, 25]. Therefore, it is probable that the inhibitory effect of *A. montanus* extracts on the activities of α -amylase and α -glucosidase may be due to the presence of these kinds of phytochemicals present in the extracts.

4. CONCLUSION

224

This study showed that methanol extract of *A. montanus* is a more potent inhibitor of α amylase and α -glucosidase than ethylacetate extract. However, this methanol extract proved to be a non-competitive and competitive inhibitor of both α -amylase and α -glucosidase respectively. It can therefore be concluded that the hypoglycemic action of this plant may be due to the inhibition these diabetes-related enzymes studied.

230 231

233 234

235

236

232 **REFERENCES**

- Koyuturk M, Ozsoy-Sacan O, Bolkent S, Yanardag R. Effect of glurenorm on immunohistochemical changes in pancreatic β-cells of rats in experimental diabetes. Indian J Exp Biol. 2005;43(3):268-7.
- Nagappa AN, Thakurdesai PA, Rao NV, Singh J. Antidiabetic activity of *Terminalia catappa* Linn fruits. J Ethnopharm. 2003;88(1):45-50.
- 239
 239
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
 240
- 4. Michael PK, Asim AB, Robert SB. The utility of oral diabetes medications in type 2 diabetes of the young. Current Diabetes Rev. 2005;1(1): 83-92.
- 5. Okoli C, Akah P, Onuoha N, Okoye T, Nwoye A, Nworu C. *Acanthus montanus*: An experimental evaluation of the antimicrobial, anti-inflammatory and immunological properties of a traditional remedy for furuncles. BMC Complem Alter Med. 2008;1(8): 27.

| 0.47 | ~ | Ornerlan FA Fruit IIO Flicks O Dime T Kentskewige D Antiinflemmeters leek |
|------------|-----|---|
| 247 | 6. | Songalem EA, Foyet HS, Ekobo S, Dimo T, Kamtchouing P. Antiinflammatory, lack |
| 248 | | of central analgesia and antipyretic properties of Acanthus montanus (Ness) T. |
| 249 | - | Anderson. J. Ethnopharm. 2004;95(1):63-8. |
| 250 | 7. | Ukwe CV, Ubaka CM. Hypoglycemic activity of leaves of <i>Acanthus montanus</i> T. |
| 251 | • | Anderson (Acanthaceae) in rats. Int J Diab Dev Count. 2011;31(1):32-6. |
| 252 | 8. | Patrick-Iwuanyanwu KC, Weghu MO. Prevention of carbon-tetrachloride (CCl ₄) |
| 253 | | induced liver damage in rats by Acanthus montanus. Asian J Biochem. |
| 254 | | 2008;3(4):213-20. |
| 255 | 9. | Foyet HS, Asongalem EA, Nana P, Folefoc GN, Kamtchouing P. Tocolytic effect of |
| 256 | | Acanthus montanus in rat uterus. Pharmacologyonline. 2006;3:9-17. |
| 257 | 10. | Nana P, Asongalem EA, Foyet HS, Folefoc GN, Dimo T, Kamtchouing P. Maternal |
| 258 | | and developmental toxicity evaluation of Acanthus montanus leaves extract |
| 259 | | administered orally to Wistar pregnant rats during organogenesis. J Ethnopharm. |
| 260 | | 2008;116(2):228-33. |
| 261 | 11. | Djami TAT, Asongalem EA, Nana P, Choumessi A, Kamtchouing P, Asonganyi T. |
| 262 | | Subacute toxicity study of the aqueous extract from Acanthus montanus. Electronic |
| 263 | | J Biol. 2011;7(1): 11-5. |
| 264 | 12. | Cheng AYY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes Mellitus. |
| 265 | | Canadian Med Assoc J. 2005;172(2):213-26. |
| 266 | 13 | Ogundajo AL, Kazeem MI, Evroh JE, Avoseh MM, Ogunwande IA. Comparative |
| 267 | 10. | study on the phytochemical composition and hypoglycemic potentials of the leaves |
| 268 | | extracts of Combretum paniculatum and Morinda morindoides. Eur J Med Pl. |
| 269 | | 2015;7(2): 77-86. |
| 209 | 11 | Mccue PP, Shetty K. Inhibitory effects of rosmarinic acid extracts on porcine |
| 270 | 14. | pancreatic α -amylase <i>in vitro</i> . Asia Pac J Cli Nutr. 2004;13(1):101-6. |
| | 15 | |
| 272 | 15. | Ali H, Houghton PJ, Soumyanath A. Alpha-amylase inhibitory activity of some |
| 273 | | Malaysian plants used to treat diabetes with particular reference to <i>Phyllanthus</i> |
| 274 | 40 | amarus. J Ethnopharm. 2006;107(3):449-55. |
| 275 | 16. | Kim YM, Jeong YK, Wang MH, Lee WY, Rhee HI. Inhibitory effects of pine bark |
| 276 | | extract on alpha-glucosidase activity and postprandial hyperglycemia. Nutr. |
| 277 | | 2005;21(6):756-61. |
| 278 | 17. | Kazeem MI, Adamson JO, Ogunwande IA. Modes of inhibition of α - amylase and α - |
| 279 | | glucosidase by Aqueous extract of Morinda lucida Benth leaf. Biomed Res Int. |
| 280 | | 2013;1-6. |
| 281 | 18. | Apostolidis E, Kwon Y-I, Shetty K. Inhibitory potential of herb, fruit, and fungal- |
| 282 | | enriched cheese against key enzymes linked to type 2 diabetes and hypertension. |
| 283 | | Innov Food Sci Emerg Tech. 2007;8(1): 46-54. |
| 284 | 19. | Kwon Y-I, Apostolidis E, Shetty K. Inhibitory potential of wine and tea against α- |
| 285 | | amylase and α-glucosidase for management of hyperglycemia linked to type 2 |
| 286 | | diabetes. J Food Biochem. 2008;32(1):15-31. |
| 287 | 20. | Mayur B, Sandesh S, Shruti S, Sung-Yum S. Antioxidant and α- glucosidase |
| 288 | | inhibitory properties of Carpesium abrotanoides L. J Med Pl Res. 2010;4(15): 1547- |
| 289 | | 53. |
| 290 | 21. | Matsuda H, Morikawa T, Yoshikawa M. Antidiabetogenic constituents from several |
| 291 | | natural medicines. Pure Appl Chem. 2002;74(7): 1301-8. |
| 292 | 22 | Kazeem MI, Ogungbe SM, Saibu GM, Aboyade OM. In vitro study on the |
| 293 | | hypoglycemic potential of <i>Nicotiana tabacum</i> leaf extracts. Bangladesh J Pharmacol. |
| 294 | | 2014;9(2): 140-5. |
| 295 | 22 | Liu X, Kim JK, Li Y, Li J, Liu F, Chen X. Tannic acid stimulates glucose transport and |
| 295 | 20. | inhibits adipocyte differentiation in 3T3-Li cells. J Nutr. 2005;135(2): 165-71. |
| 290 297 | 24 | Yang C-Y, Wang J, Zhao Y, Shen L, Jiang X, Xie Z-G. et al. Anti-diabetic effects of |
| 297 | 24. | Panax notoginseng saponins and its major anti-hyperglycemic components. J |
| 298 299 | | |
| 299 | | Ethnopharm. 2010;130(2): 231-6. |

 Zheng T, Shu G, Yang Z, Mo S, Zhao Y, Mei Z. Antidiabetic effect of total saponins from *Entada phaseoloides* (L.) Merr. in type 2 diabetic rats. J Ethnopharm. 2012; 139(3): 814-21.

303

300 301 302